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Over the last decade, the emergence of a vast range of new/novel/emerging psychoactive
substances (NPS) has progressively changed drug market scenarios, which have shifted from the
‘street’ to a ‘virtual’/online environment.
Several definitions of NPS are in use, with the term ‘new’ not necessarily referring to new
inventions but to substances that have recently been made available, possibly including failed
pharmaceuticals or old patents which have been ‘rediscovered’ as ‘recreational’ molecules. Conversely,
the term ‘novel’ can refer to something newly created, an old drug that has come back into fashion,
or a known NPS molecule being used in an innovative or unusual way and hence presenting
a ‘novelty’ appeal (Corkery et al., 2018) [1]. Though misleading, the terms ‘legal highs’ and
‘research chemicals’ have been used alternately to describe these molecules. NPS includes synthetic
cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids,
tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists,
a range of prescribed medications, psychoactive plants/herbs, and a large series of image- and
performance-enhancing drugs (IPED) (Schifano et al., 2015) [2]. Overall, users are typically attracted
to NPS because of curiosity and the diffusion of social media users’ experiences, easy availability or
affordability from online drug shops, legality, intense psychoactive effects, and the likely lack of detection
in routine drug screenings (Schifano et al., 2015) [2].
Between 2004 and 2017, some 700–800 examples of NPS were reported by related European and
international drug agencies (UNODC, 2018 [3]; EMCDDA, 2018 [4]), with most molecules identified
being synthetic cannabinoids, synthetic cathinones, phenethylamine derivatives, and synthetic opioids.
However, it could be argued that the NPS scenario is much larger than that outlined by those molecules
which have been seized or formally identified by EU and international agencies. Since the online NPS
scenario typically predicts the real life NPS scenario (Schifano et al., 2015) [2], identifying what is being
discussed online by web-based NPS enthusiasts, or ‘e-psychonauts’ (Orsolini et al., 2015) [5], may well
be of interest. With this in mind, a crawling/navigating software (i.e., the ‘NPS.Finder®’) was recently
designed by our group. In November 2017, it started to automatically scan, on a 24/7 basis, a vast
range of psychonaut web forums for NPS. After a year of operation, it has been possible to estimate that
the online/psychonaut web forum NPS scene may include some 4000 different molecules. The most
popular examples of NPS mentioned in psychonaut forums have included synthetic cannabimimetics,
synthetic opioids, phenethylamines, designer benzodiazepines, and prescribed drugs.
NPS use, especially for synthetic cannabinoids and novel psychedelics, has been associated with
a range of untoward medical consequences, including vomiting, seizures, cardiovascular complications,
and kidney failure (Schifano et al., 2017) [6]. By contrast, the main focus of this special issue is on the
major psychopathological consequences of NPS use. Indeed, due to their complex pharmacodynamics,
there are increasing levels of concern about the onset of acute or chronic psychopathological issues
associated with NPS intake.
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The occurrence of psychosis has been related to: (a) increased central dopamine levels, typically
seen with novel psychedelic phenethylamines, novel stimulants and synthetic cathinones; (b) significant
cannabinoid CB1 receptor activation, which is associated with high potency synthetic cannabimimetics;
(c) 5-HT2A receptor activation, seen with latest generation phenethylamines, tryptamine derivatives and
hallucinogenic plants; (d) antagonist activity at n-methyl-D-aspartate/NMDA receptors, observed with
ketamine, methoxetamine/MXE, and their latest derivatives; and (e) k-opioid receptor activation,
which is typically associated with both Salvia divinorum and Mitragyna speciosa/‘Kratom’ intake.
By considering the above, this special issue of Brain Sciences aims to provide an overview of a range
of NPS-related issues. More precisely, Sahai et al. [7] present original preclinical data relating in silico and
in vitro assessment of the psychoactive properties of a few dissociative diarylethylamines. Miolo et al. [8]
focus on specific analytical chemistry issues relating to amphetamine-type stimulants and ketamine,
while Parrott [9] argues that there are similarities between well-known recreational drugs and NPS in terms
of mood fluctuations/psychobiological instability issues. Conversely, Cohen and Weinstein [10] present original
cognitive psychopharmacology data relating to the use of organic and synthetic cannabinoids. From a clinical
point of view, Bonaccorso et al. [11] introduce a case series of synthetic cannabinoid users presenting
to acute psychiatric services with psychosis; Frisoni et al. [12] comment on the medical consequences
of novel opioid intake; Martinotti et al. [13] provide a thorough overview of hallucinogen-persisting
perceptual disorder, a clear issue of interest for NPS users; Schifano et al. [14] reflect on the misuse
and abuse of prescribed medicines (e.g., benzodiazepine derivatives, methylphenidate look-alikes,
and fentanyl analogues) in the NPS context; and Gittins et al. [15] provide empirical data relating NPS
use by clients seeking treatment in the UK. Both Wadsworth et al. [16] and Miliano et al. [17] comment
extensively on the role of the open/deep web in shaping and promoting changes in NPS scenarios. Finally,
both Metastasio et al. [18] and Catalani et al. [19] offer original data which sheds further light on the
expanding phenomenon of IPED misuse/abuse.
In conjunction with constant changes in basic structures from which emerging molecules can
be derived, designed, and synthesized, the NPS market will continue to expand. This will pose
a challenge, since NPS-related toxidromes are, per se, complex and unpredictable, and clinicians need
to aim to be better educated in recognizing NPS-related toxicity issues. Drug control policies should be
improved worldwide, and the list of examples of NPS should be constantly updated as improvements
in analytical chemistry detection methods occur. Given the implications of NPS for mental health,
psychiatric services should adapt to new drug scenarios while drafting new treatment strategies.
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